drugset / Trial / NCT05905731
Autologous T-cells Transfected With mRNA Encoding HBV-TCR T Cell Therapy in Combination With NUC for Chronic Hepatitis B
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open label study to assess the safety, tolerability and effectiveness of the autologous HBV specific T cell receptor (HBV-TCR) redirected T cells in patients with chronic hepatitis B with ongoing with nucleos(t)ide analogue (NUC) treatment. This study will be conducted sequentially starting with Stage-1, followed by Stage-2.
Timeline
- Start
- 2023-06-01
- Primary completion
- 2025-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TCR-T | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | TCR-T | Cell therapy | 5e+06 cells/kg | Intravenous |